BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32823413)

  • 41. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
    Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
    Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diabetic Macular Edema and Diode Subthreshold Micropulse Laser: A Randomized Double-Masked Noninferiority Clinical Trial.
    Lois N; Campbell C; Waugh N; Azuara-Blanco A; Maredza M; Mistry H; McAuley D; Acharya N; Aslam TM; Bailey C; Chong V; Downey L; Eleftheriadis H; Fatum S; George S; Ghanchi F; Groppe M; Hamilton R; Menon G; Saad A; Sivaprasad S; Shiew M; Steel DH; Talks JS; Doherty P; McDowell C; Clarke M;
    Ophthalmology; 2023 Jan; 130(1):14-27. PubMed ID: 35973593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data.
    Muston D; Korobelnik JF; Reason T; Hawkins N; Chatzitheofilou I; Ryan F; Kaiser PK
    BMC Ophthalmol; 2018 Dec; 18(1):340. PubMed ID: 30591022
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
    Sahni J; Patel SS; Dugel PU; Khanani AM; Jhaveri CD; Wykoff CC; Hershberger VS; Pauly-Evers M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Osborne A; Weikert R; Fauser S
    Ophthalmology; 2019 Aug; 126(8):1155-1170. PubMed ID: 30905643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
    Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusions: A Systematic Review and Meta-Analysis.
    Spooner K; Hong T; Fraser-Bell S; Chang A
    Asia Pac J Ophthalmol (Phila); 2019; 8(3):236-246. PubMed ID: 31132002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and follow-up of anti-VEGF injections in diabetic macular edema in real-life practice at the Dijon university medical centre through the Save Sight Registries.
    Tessier M; Meillon C; Creuzot-Garcher C; Bron AM; Nguyen P
    J Fr Ophtalmol; 2020 Sep; 43(7):618-625. PubMed ID: 32473741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
    Laugesen CS; Ostri C; Brynskov T; Lund-Andersen H; Larsen M; Vorum H; Sørensen TL
    Acta Ophthalmol; 2017 Feb; 95(1):28-32. PubMed ID: 27473397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
    Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidemic retinitis - Factors associated with poor visual outcomes.
    Kawali A; Sanjay S; Mahendradas P; Mohan A; Shetty B
    Indian J Ophthalmol; 2022 Mar; 70(3):897-901. PubMed ID: 35225539
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early effect of simultaneous intravitreal dexamethasone and bevacizumab combination treatment in patients with persistent diabetic macular edema.
    Limon U
    J Fr Ophtalmol; 2021 Jun; 44(6):849-854. PubMed ID: 33840497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.
    Rajendram R; Fraser-Bell S; Kaines A; Michaelides M; Hamilton RD; Esposti SD; Peto T; Egan C; Bunce C; Leslie RD; Hykin PG
    Arch Ophthalmol; 2012 Aug; 130(8):972-9. PubMed ID: 22491395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy.
    Bakri SJ; Larson TA
    Semin Ophthalmol; 2015 Jul; 30(4):276-80. PubMed ID: 24251435
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes.
    Schefler AC; Fuller D; Anand R; Fuller T; Moore C; Munoz J; Kim RS;
    Am J Ophthalmol; 2020 Aug; 216():165-173. PubMed ID: 32278771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-life anti-vascular endothelial growth factor treatment for age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital.
    Battaglia Parodi M; Romano F; Arrigo A; Sacchi R; Scanzi G; Ferri C; Bandello F
    Eur J Ophthalmol; 2020 Nov; 30(6):1461-1466. PubMed ID: 31617403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes.
    Ciulla T; Pollack JS; Williams DF
    Br J Ophthalmol; 2021 Dec; 105(12):1696-1704. PubMed ID: 33055088
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravitreal anti-vascular endothelial growth factor with and without topical non-steroidal anti-inflammatory in centre-involving diabetic macular edema.
    Mohan S; Chawla G; Surya J; Raman R
    Indian J Ophthalmol; 2021 Nov; 69(11):3279-3282. PubMed ID: 34708787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.